Archive for October, 2008

JCNN News Summaries - Japan Corporate News Network - Eisai Announces Establishment of its Pharmaceuticals Marketing

Friday, October 31st, 2008

Eisai Co., Ltd. (TSE:4523) announced today that on October 27, 2004, it had established its pharmaceuticals marketing subsidiary, Eisai Pharmaceuticals India Private Ltd. in India.
In India, Eisai Pharmaceuticals India Private Ltd. will sell and promote pharmaceuticals developed by Eisai including ARICEPT, an Alzheimer’s disease …

Men’s Health Advisor - Reflux drugs may raise risk of hip fracture

Friday, October 24th, 2008

Acid-suppressing drugs known as proton pump inhibitors (PPIs), frequently prescribed for people with gastroesophageal reflux disease, may raise the risk of hip fracture, according to a study in the Dec. 27 issue of the Journal of the American Medical Association. PPIs include esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Pri…

Kiplinger Letter, The - Relief is in sight on Rx drug costs.(HEALTH COSTS)(Brief Article)

Sunday, October 19th, 2008

Relief is in sight on Rx drug costs: A pillbox of new generics is coming. Antidepressants Celexa, Zoloft and Wellbutrin, ulcer-fighters Prevacid and Aciphex and cholesterol-lowering Pravachol and Zocor will all lose patent protection over the next three years.

Relate…

Medical Marketing and Media - Eisai, Janssen educate consumers on acid reflux

Wednesday, October 15th, 2008

EISAI AND Janssen Pharmaceutica have launched a consumer education program to promote awareness of gastroesophageal acid reflux disease, or GERD, for which they co-market the proton pump inhibitor Aciphex.
The “Gut and Gurgle University” campaign, which is being executed by Dorland Global Health Communications, features events at shopping malls across the country designed to drive consumers to a Web site (www.gutandgurgleu.com). The site provides frequently ask…

Business Wire - Eisai Debuts Newly Expanded Facility; Company’s rapid growth spurs expansion of facility to accommodate increased production and pharmaceutical R&D activities

Sunday, October 12th, 2008

Business Editors/Health & Medical Writers
FEASTERVILLE, Pa.–(BW HealthWire)–April 30, 2001
According to Cognet-X, Inc.’s PAR-Rx (Promotional Assessment Research) Report(TM), the top 10 prescription medicines most heavily promoted to managed care pharmacy directors during the first quarter…

JCNN News Summaries - Japan Corporate News Network - Eisai Establishes Pharmaceuticals Marketing Subsidiary in India

Friday, October 10th, 2008

Eisai (TSE: 4523) has announced the establishment of a pharmaceuticals marketing subsidiary, Eisai Pharmaceuticals India Private Ltd. in India.
The new subsidiary will sell and promote pharmaceuticals de…

Best Canadian Online Pharmacy at Rxhealthsuperstore.com

Wednesday, October 8th, 2008

Buy Paroxetine Tablets
Buy Online Paroxetine is used for Treating depression or obsessive-compulsive disorder . It may be used to treat panic disorder or posttraumatic stress disorder. It may also be used to treat generalized anxiety disorder or social anxiety disorder. It may also be used for other conditions as determined by your doctor. Cheap Paroxetine is a selective serotonin reuptake inhibitor. It works by restoring …

Economic Times (New Delhi, India) - Dr Reddy’s Labs expects verdict in Aciphex case by May 15.

Sunday, October 5th, 2008

Byline: Rajesh Unnikrishnan
Apr. 6–MUMBAI, India — As the patent clash between Dr Reddy’s Labs (DRL) and Japanese pharma firm Eisai for the control over $1.3-billion anti-ulcer drug Aciphex enters the last lap in the US, investors and analysts are pinning hopes on DRL. If the Indian pharma major wins, it may bring in a fortune to DRL.
DRL is fighting the case along with Israel pharma fir…